Horizon Pharma plc (HZNP) : Tuesdays money flow data in Horizon Pharma plc (HZNP) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $10.37 million, whereas, $8.27 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.25, in favor of the bulls. The total money flow into the stock was $2.1 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $3.69 million. The total value of block trades done on upticks was $3.98 million. The value of bearish trades on downticks was only $0.29 million.The up/down ratio in the block trades was a healthy 13.89 in favor of the bulls, suggesting strong buying in the stock by large traders. Horizon Pharma plc (HZNP) fell $0.12 and traded at $19, down -0.63% for the day, over previous days close. On a weekly basis, the shares are 1.55% over the previous weeks close.
The company Insiders own 2.1% of Horizon Pharma plc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.64% . Institutional Investors own 86.84% of Horizon Pharma plc shares. During last six month period, the net percent change held by insiders has seen a change of -7.9%. In an insider trading activity, The director, of Horizon Pharma Plc, Nohria Virinder had unloaded 25,000 shares at $17.69 per share in a transaction on June 15, 2016. The total value of transaction was $442,250. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Shares of Horizon Pharma plc rose by 12.98% in the last five trading days and 5.65% for the last 4 weeks. Horizon Pharma plc is up 40.76% in the last 3-month period. Year-to-Date the stock performance stands at -12.83%.
Horizon Pharma plc (NASDAQ:HZNP): On Tuesdays trading session , Opening price of the stock was $19.34 with an intraday high of $19.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $18.85. However, the stock managed to close at $18.89, a loss of 1.20% for the day. On the previous day, the stock had closed at $19.12. The total traded volume of the day was 4,355,377 shares.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.